In this multicenter study, patients at high risk of psychosis will have the opportunity to participate in a therapy specifically adapted to them by means of individual risk diagnostics, with the help of which the development of a first psychotic episode is to be prevented. The therapy program is expected to start towards the end of 2022 and will offer weekly therapy sessions for participating patients over a period of about 4-6 months.